The staging of malignant melanoma and the Florida Melanoma Trial.

Douglas S. Reintgen, James W. Jakub, Solange Pendas, Gray Swor, Rosemary Giuliano, Steve Shivers

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Lymphatic mapping and sentinel lymph node (SLN) biopsy have changed the standard of care for patients with malignant melanoma, by providing a less morbid procedure to obtain the nodal staging information that is critical for therapeutic decisions. Detailed examination of the SLN identifies patients who have an increased risk for recurrence and death. Patients whose melanoma is upstaged with very sensitive assays based on reverse transcriptase polymerase chain reaction technology are better targeted for clinical trials or surgical or adjuvant therapies. In the future, melanoma may be "ultrastaged" by examining the SLNs, peripheral blood, and bone marrow. This may improve identification of patients who are surgically cured of their disease and therefore can be spared the side effects of more radical surgery or the toxicities of adjuvant therapy. The lymphatic mapping procedure is the most accurate way to determine the tumor status of the regional lymph nodes.

Original languageEnglish (US)
Pages (from-to)186S-91S
JournalAnnals of surgical oncology : the official journal of the Society of Surgical Oncology
Volume11
Issue number3 Suppl
StatePublished - Mar 2004

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'The staging of malignant melanoma and the Florida Melanoma Trial.'. Together they form a unique fingerprint.

Cite this